Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer

NCT04009941 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT04009941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04009941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Lead sponsor
Peking University
Phase
Phase 4
Overall status
Completed
Start date
August 1, 2019
Completion date
January 31, 2020
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neutropenia